MentiNova Inc., a developer of an oral medication to help treat symptoms of Parkinson’s disease, has raised $500k in funding.
The capital was provided by Foundation Venture Capital Group.
Co-founded by Dr. M. Maral Mouradian, the William Dow Lovett Professor of Neurology and Director of the Center for Neurodegenerative and Neuroimmunologic Diseases at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School in Piscataway, NJ, the company is exploring an oral medication that could reduce uncontrollable, often chaotic movements in patients being treated with L-Dopa.
The funds will be used to advance the status of its IND (Investigational New Drug) filing with the FDA and to perform clinical trials testing the efficacy of the treatment.
Research to date has provided in-vivo proof of principle data.